Thymosin Alpha-1 (TA-1) Testing

MW: 3108.32 g/molHalf-life: ~2 hoursStatus: Approved as Zadaxin in many countries

28-residue thymic peptide; immunomodulator approved for hepatitis B/C in some countries (Zadaxin).

Mechanism of action

28-residue thymic peptide that modulates T-cell development and function via Toll-like receptor signaling. Augments Th1 immune response; approved in >35 countries for chronic hepatitis B/C and as adjuvant to vaccines.

Sequence & structure

Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN (28 residues, N-acetylated)

N-terminal acetylation is essential — deacetylated forms have lower activity. Acidic peptide (pI ~4.2).

Research areas

  • Chronic viral infection (HBV, HCV)
  • Cancer immunotherapy adjuvant
  • Sepsis (CASS trial)
  • Vaccine response in elderly

What we test on Thymosin Alpha-1 (TA-1)

RP-HPLC, intact mass, N-acetyl confirmation by MS/MS, mandatory LAL endotoxin for injectable lots.

Standard Immune & Anti-Inflammatory Panel
  • RP-HPLC purity
  • ESI-MS identity
  • Endotoxin (LAL, USP <85>)
  • SEC for LL-37 aggregation

Common impurities & failure modes

  • Deacetylated TA-1

    −42 Da; reduced activity.

  • Deamidation (Asn26)

    Stability indicator.

  • Truncation

    Particularly at the C-terminal acidic stretch.

  • Endotoxin

    Immunomodulators must be endotoxin-free; LAL mandatory.

Regulatory status

Approved as Zadaxin in many countries (not FDA-approved in US).

Related Immune & Anti-Inflammatory peptides